Howtian’s enzyme-modified steviol glycosides receive “no questions” letter for GRAS notice from FDA

The GRAS notice was submitted by GRAS Associates, a fully owned subsidiary of Nutrasource, on behalf of Howtian.

Howtian, a Chinese company formerly known as Zhucheng Haotian Pharma Co. Ltd., has received its second “no questions” GRAS (generally recognized as safe) letter from the U.S. Food and Drug Administration (FDA) for another stevia sweetener product. The GRAS notice was submitted by GRAS Associates, a fully owned subsidiary of Nutrasource (Guelph, ON, Canada), on behalf of Howtian.

“GRAS Associates is pleased to have assisted adding another steviol glycoside preparation into the Howtian portfolio permitted for import and use in the U.S. marketplace with the successful GRAS conclusion and notification to FDA for their enzyme-modified steviol glycosides (GRN 999),” said Amy Mozingo, vice president of U.S. nutra regulatory sciences for Nutrasource/GRAS Associates, in a press release.

“Nutrasource was instrumental in outlining all the documents we needed to provide for the best chance for a seamless review by the FDA,” noted Hank Wang, technical director at Howtian. “The positive results from both our recent GRAS applications showed that they were a great partner to collaborate with.”